Post-operative nomogram for predicting freedom from recurrence after surgery in localised breast cancer receiving adjuvant hormone therapy.

Archive ouverte

Mazouni, C | Fina, F | Romain, S | Bonnier, P | Ouafik, L | Martin, P-M

Edité par CCSD ; Springer Verlag -

International audience. PURPOSE: To develop a prognostic nomogram to predict freedom from recurrence for patients treated with adjuvant hormonal therapy (HT) for localised breast cancer (BC).METHODS: We performed a retrospective analysis of 142 patients treated with adjuvant HT between 1996 and 2000. Clinical and pathological parameters were analysed.RESULTS: A nomogram that predicts the probability of remaining free of recurrence for 5 years after surgery with adjuvant HT was developed using a Cox proportional hazards regression model. The progesterone receptor status (p < 0.001), nodal status (p = 0.008) and cathepsin-D (p < 0.001) were retained to construct the nomogram (C-index 0.734).CONCLUSIONS: The nomogram we developed may be useful for estimating the probability of successful treatment 5 years after surgery for localised BC.

Consulter en ligne

Suggestions

Du même auteur

Outcome of Epstein-Barr virus-associated primary breast cancer.

Archive ouverte | Mazouni, C | CCSD

International audience. The presence of the Epstein-Barr-virus (EBV) has been reported to be a pathogenic factor in breast cancer (BC). We previously demonstrated the aggressiveness of EBV-positive BC. The purpose o...

Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma. Bénéfice à l’évaluation moléculaire en routine pour les cancers bronchiques métastatiques

Archive ouverte | Fournier, C | CCSD

International audience. BACKGROUND: EGFR tyrosine kinase inhibitors and crizotinib are nowadays the optimal treatment for metastatic lung cancer with activation of EGFR mutations and ALK rearrangement. In addition, ...

Immunohistochemical hormonal mismatch and human epidermal growth factor type 2 [HER2] phenotype of brain metastases in breast cancer carcinoma compared to primary tumors. Discordance du phénotype immunohistochimique hormonal et du récepteur du facteur de croissance épidermique de type 2 [HER2] des métastases cérébrales de cancer du sein comparativement à leurs primitifs

Archive ouverte | Joubert, C | CCSD

International audience. INTRODUCTION: Phenotype changes between primary tumor and the corresponding brain metastases are recent reported data. Breast cancer, with biological markers predicting prognosis and guiding ...

Chargement des enrichissements...